Related references
Note: Only part of the references are listed.Usefulness of antidiabetic alpha-glucosidase inhibitors: a review on the timing of administration and effects on gut hormones
Kazutaka Aoki et al.
ENDOCRINE JOURNAL (2019)
Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin
Pai-Feng Hsu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data
Evgenia Gourgari et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2017)
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
Rury R. Holman et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Efficacy of acarbose in different geographical regions of the world: analysis of a real-life database
Jianping Weng et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2015)
Efficacy of adding once- and thrice-daily voglibose in Japanese type 2 diabetic patients treated with alogliptin
Mitsuyoshi Takahara et al.
ENDOCRINE JOURNAL (2014)
Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report
Miao-yan Zheng et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Comparison of the Hypoglycemic Effect of Acarbose Monotherapy in Patients With Type 2 Diabetes Mellitus Consuming an Eastern or Western Diet: A Systematic Meta-analysis
Qibo Zhu et al.
CLINICAL THERAPEUTICS (2013)
A Prospective, Randomized, Open-Label Study Comparing the Efficacy and Safety of Preprandial and Prandial Insulin in Combination with Acarbose in Elderly, Insulin-Requiring Patients with Type 2 Diabetes Mellitus
Guang Yang et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2013)
Early Improvement in Carotid Plaque Echogenicity by Acarbose in Patients With Acute Coronary Syndromes
Mitsumasa Hirano et al.
CIRCULATION JOURNAL (2012)
Acarbose treatments improve arterial stiffness in patients with type 2 diabetes mellitus
Hiroyasu Uzui et al.
JOURNAL OF DIABETES INVESTIGATION (2011)
Impact of Acarbose on Carotid Intima-Media Thickness in Patients With Newly Diagnosed Impaired Glucose Tolerance or Mild Type 2 Diabetes Mellitus: A One-Year, Prospective, Randomized, Open-Label, Parallel-Group Study in Japanese Adults With Established Coronary Artery Disease
Masayoshi Koyasu et al.
CLINICAL THERAPEUTICS (2010)
The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus
Takeshi Osonoi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2010)
Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients
Mihoko Matsumura et al.
ADVANCES IN THERAPY (2009)
Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients
T. Narita et al.
DIABETIC MEDICINE (2009)
The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance
H. Laube et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2009)
Effect of acarbose, an alpha-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in type 2 diabetes mellitus treated by sulfonylurea
Tomokazu Oyama et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2008)
Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy
O. Schnell et al.
DIABETES OBESITY & METABOLISM (2007)
alpha-Glucosidase inhibitors for patients with type 2 diabetes - Results from a cochrane systematic review and meta-analysis
FA van de Laar et al.
DIABETES CARE (2005)
Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Review) - art. no. CD003639.pub2
FA Van de Laar et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2005)
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies
M Hanefeld et al.
EUROPEAN HEART JOURNAL (2004)
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance - The STOP-NIDDM Ttrial
JL Chiasson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Acarbose improves glycemic control in overweigh type 2 diabetic patients insufficiently treated with metformin
P Phillips et al.
DIABETES CARE (2003)
Acarbose in the treatment of elderly patients with type 2 diabetes
RG Josse et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2003)
Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects
MJ DeLeon et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2002)
Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients
A Vichayanrat et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2002)
Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release
FY Enç et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2001)
Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study
G Mertes
DIABETES RESEARCH AND CLINICAL PRACTICE (2001)
The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes
JL Chiasson et al.
DIABETES CARE (2001)
Glucose tolerance and cardiovascular mortality -: Comparison of fasting and 2-hour diagnostic criteria
K Borch-Johnsen et al.
ARCHIVES OF INTERNAL MEDICINE (2001)
Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study
S Halimi et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2000)
Share Paper
